Summary
TIL therapy marks a major shift in solid-tumor immunotherapy, offering an effective approach where CAR-T strategies have struggled, broadening options beyond PD-1 and BRAF/MEK inhibitors for metastatic melanoma, and driving extensive clinical evaluation across NSCLC, HNSCC, CRC, pancreatic, prostate, cervical, and other cancers.
Iovance’s AMTAGVI (lifileucel) has emerged as the first approved personalized TIL treatment, earning accelerated FDA authorization for advanced melanoma after PD-1 therapy.
Its approval has catalyzed a surge in competitive development, with companies such as Obsidian Therapeutics (OBX-115), KSQ Therapeutics ...
